Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1

BACKGROUND & AIMS: Although cancer immunotherapies are effective for advanced-stage cancers, there are no clinically approved immunotherapies for colon cancers (CRCs). Therefore, there is a high demand for the development of novel therapies. Extracellular adenosine-mediated signaling is consider...

Descripción completa

Detalles Bibliográficos
Autores principales: Noh, Ji-Yoon, Lee, In Pyo, Han, Na Rae, Kim, Miok, Min, Yong Ki, Lee, Sang-Yeop, Yun, Sung Ho, Kim, Seung Il, Park, Tamina, Chung, Hyunmin, Park, Daeui, Lee, Chang Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424593/
https://www.ncbi.nlm.nih.gov/pubmed/35843546
http://dx.doi.org/10.1016/j.jcmgh.2022.07.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424593/
https://www.ncbi.nlm.nih.gov/pubmed/35843546
http://dx.doi.org/10.1016/j.jcmgh.2022.07.005

Ejemplares similares